Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evusheld for COVID-19 Immunity in Vaccine Non-responsive CLL
NCT05465876Phase 2Withdrawn
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Sunnybrook Health Sciences Centre. Planned start Oct 2023; status: withdrawn.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05465876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465876.